Yüklüyor......
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
Molecule-targeted therapy has achieved great progress in cancer therapy. Effective drug combinations are one way to enhance the therapeutic efficacy and combat resistance. Here, we determined the effect of the PI3K/mTOR dual inhibitor BEZ235 and the histone deacetylase inhibitor Trichostatin A (TSA)...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355316/ https://ncbi.nlm.nih.gov/pubmed/28060760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14442 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|